{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:32:24Z","timestamp":1775064744544,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T00:00:00Z","timestamp":1344211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Etoricoxib, a selective inhibitor of cyclooxygenase 2, is increasingly used in pain relief. Here, we report the first case of etoricoxib\u2010induced immune hemolytic anemia.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> An 84\u2010year\u2010old male patient developed anemia 1\u2003week after treatment with etoricoxib. There was no evidence of hemoglobinemia or hemoglobinuria. Administration of the drug was halted, and the patient recovered without further complications.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> The patient's red blood cells (RBCs) were found to be strongly coated with immunoglobulin\u2003G and C3d. Eluted antibodies and dialyzed serum from the patient were not reactive with untreated RBCs, but with etoricoxib\u2010treated RBCs, RBCs in the presence of etoricoxib, urine containing drug metabolites (ex vivo antigen), and two of four additional COX inhibitor drugs analyzed.<\/jats:p><jats:p><jats:bold>DISCUSSION:<\/jats:bold> Although the causative antibodies were drug dependent usually leading to abrupt and intravascular hemolysis, the patient only gradually developed anemia. These findings together with a positive direct and indirect antiglobulin test may lead to confusion with autoimmune hemolytic anemia of warm type. A nonreactive eluate was the key serologic finding in identifying drug\u2010induced immune hemolytic anemia in this case.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Etoricoxib should be considered as a risk in the development of immune hemolytic anemia, with the causative antibodies potentially reacting with other COX inhibitors.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03843.x","type":"journal-article","created":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T07:00:01Z","timestamp":1344236401000},"page":"1033-1036","source":"Crossref","is-referenced-by-count":7,"title":["The first example of a patient with etoricoxib\u2010induced immune hemolytic anemia"],"prefix":"10.1111","volume":"53","author":[{"given":"Beate","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Genth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Dehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulgabar","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,6]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802577351"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb01309.x"},{"key":"e_1_2_8_4_2","volume-title":"Immune hemolytic anemias","author":"Petz LD","year":"2004"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196703232761203"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198409273111301"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21307\/immunohematology-2019-328","article-title":"An update on drug\u2010induced immune haemolytic anemia","volume":"23","author":"Garratty G","year":"2007","journal-title":"Immunohematology"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7563"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40060663.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847110-00002"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1947.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(90)70249-0"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04484.x"},{"key":"e_1_2_8_14_2","first-page":"2","article-title":"Drug\u2010induced immune thrombocytopenia: an overview of pathogenesis","volume":"36","author":"Aster RH","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1309\/JFJE-VUKN-221T-G6EV"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02028.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03843.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03843.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T18:44:58Z","timestamp":1697309098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03843.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,6]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03843.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03843.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,6]]}}}